Bronchial asthma
Conditions
Interventions
Budesonide group Pulmicort (200mcg) Turbuhaler one inhalation, twice daily for 24 weeks
Budesonide/formoterol group Symbicort (160/4.5mcg) Turbuhaler one inhalation, twice daily for 24 weeks
Sponsors
Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Adult outpatient with mild persistent and moderate asthma 2)Patient with inhaled steroid naive 3)Nonsmoking patient 4)Patients who has provided written consent prior to enrollment
Exclusion criteria
Exclusion criteria: 1)Patients with a history of hypersensitivity (including contact dermatitis) to any ingredient contained in the budesonide/formoterol combination 2)Patients with infectious with no available effective antimicrobial drugs or with deep-seated mycosis 3)Patients with other respiratory illnesses (including lung cancer, tuberculosis, bronchiectasis) 4)Patients with heart failure 5)Patients who contracted a respiratory infection that could influence asthma within the last 4 weeks 6)Patients who ere treated with systemic corticosteroids in the last 4 weeks 7)Patients with RE 8)Patients with other severe diseases 9)Patients who are considered inappropriate by the physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline (Week 0) in the airway hyperresponsiveness at Week 2, 4, 8 and 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline (Week 0) in the following clinical variables at Week 2, 4, 8 and 24 1) ACQ 2) Respiratory function 3) Exhaled nitric oxide | — |
Countries
Japan
Contacts
Public ContactKazuto Matsunaga
Wakayama Medical University, School of Medicine Third Department of Internal Medicine
Outcome results
None listed